Fig. 5

In vivo activity of NILK-2301 in two xenograft models using NOG mice. LS-174 T human PBMCs co-grafting model (upper panel) and HPAF-II PBMCs IV humanized model (lower panel). A, D Schematic representation of the experimental set up, and B, E tumor volume over time. C Tumor volume at day 21. F Tumor volume at day 18. Statistical analysis was performed on tumor volume at day 21 (LS-174 T) or day 18 (HPAF-II), respectively, using Mann–Whitney U test. *P < 0.05 and **P < 0.01. TV, tumor volume; D, day; GvHD, host-versus-graft disease; SC, subcutaneously; IV, intravenously